Stock Price
2.17
Daily Change
-0.18 -7.66%
Monthly
-3.98%
Yearly
69.53%
Q2 Forecast
2.06

Galectin Therapeutics reported $-9.17M in EBIT for its fiscal quarter ending in September of 2023.





Ebit Change Date
AbbVie USD 4.73B 1.08B Mar/2026
Bristol-Myers Squibb USD 3.56B 90M Mar/2026
Galectin Therapeutics USD -9.17M 163K Sep/2023
Gilead Sciences USD 2.68B 284M Mar/2026
Immunic USD -23.33M 2.67M Dec/2025
Incyte USD 344.17M 39.71M Mar/2026
Merck USD -1.88B 8.12B Mar/2026